NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML SOLUTION

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

NITROGLYCERIN; DEXTROSE

זמין מ:

BAXTER CORPORATION

קוד ATC:

C01DA02

INN (שם בינלאומי):

GLYCERYL TRINITRATE

כמות:

20MG; 5G

טופס פרצבטיות:

SOLUTION

הרכב:

NITROGLYCERIN 20MG; DEXTROSE 5G

מסלול נתינה (של תרופות):

INTRAVENOUS

יחידות באריזה:

250ML

סוג מרשם:

Ethical

איזור תרפויטי:

NITRATES AND NITRITES

leaflet_short:

Active ingredient group (AIG) number: 0227179001; AHFS:

מצב אישור:

MARKETED

תאריך אישור:

1995-12-31

מאפייני מוצר

Page 1 of 18
PRODUCT MONOGRAPH
NITROGLYCERIN IN 5% DEXTROSE INJECTION
25 mg Nitroglycerin in 5% Dextrose Inj. 250mL
50 mg Nitroglycerin in 5% Dextrose Inj. 250mL
100 mg Nitroglycerin in 5% Dextrose Inj. 250mL
Professed Standard
VASODILATOR
Baxter Corporation
Revision Date: October 30, 2017
Mississauga, Ontario L5N 0C2
Submission Control No: 206985
Baxter is a registered trademark of Baxter International Inc.
Page 2 of 18
PRODUCT MONOGRAPH
NITROGLYCERIN IN 5% DEXTROSE INJECTION
25 mg Nitroglycerin in 5% Dextrose Inj. 250mL
50 mg Nitroglycerin in 5% Dextrose Inj. 250mL
100 mg Nitroglycerin in 5% Dextrose Inj. 250mL
Professed Standard
VASODILATOR
ACTIONS AND CLINICAL PHARMACOLOGY
The principal pharmacological action of Nitroglycerin in 5% Dextrose
Injection is relaxation of
vascular smooth muscle and consequent dilation of peripheral arteries
and veins, especially the
latter. Nitrates probably act primarily by reducing oxygen demand
rather than by increasing
myocardial oxygen supply. Dilation of the veins promotes peripheral
pooling of blood and
decreases venous return to the heart, thereby reducing left
ventricular end-diastolic pressure
and pulmonary capillary wedge pressure (preload). Arteriolar
relaxation reduces systemic
vascular resistance, systolic arterial pressure, and mean arterial
pressure (afterload). Dilation of
the coronary arteries also occurs. The relative importance of preload
reduction, afterload
reduction, and coronary dilation remains undefined.
Blinded, placebo-controlled trials of intravenous nitroglycerin have
not been reported, but
multiple investigators have reported open-label studies, and there are
scattered reports of
studies
in
which
intravenous
nitroglycerin
was
tested
in
blinded
fashion
against
sodium
nitroprusside.
In each of these studies, therapeutic doses of intravenous
nitroglycerin were found to reduce
systolic and diastolic arterial blood pressure. The heart rate was
usually increased, presumably
as a reflexive response to the fall in blood pressure. Coronary
perfusion pressure